• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Henry Schein Appoints Trinh Clark and Leigh Benowitz to Executive Management Committee

    8/1/22 4:05:00 PM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    • Clark Named to New Position as Chief Global Customer Experience Officer
    • Benowitz Named to New Position as Chief Global Digital Transformation Officer
    • Appointments Advance Implementation of 2022-2024 BOLD+1 Strategic Plan

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today the appointment of two executives – Trinh Clark and Leigh Benowitz – to the Company's Executive Management Committee.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005699/en/

    Pictured left to right: Trinh Clark, Senior Vice President and Chief Global Customer Experience Officer, and Leigh Benowitz, Senior Vice President and Chief Global Digital Transformation Officer of Henry Schein, Inc. (Photo: Business Wire)

    Pictured left to right: Trinh Clark, Senior Vice President and Chief Global Customer Experience Officer, and Leigh Benowitz, Senior Vice President and Chief Global Digital Transformation Officer of Henry Schein, Inc. (Photo: Business Wire)

    The appointment of Ms. Clark and Ms. Benowitz to the Executive Management Committee advances the implementation of Henry Schein's 2022-2024 BOLD+1 Strategic Plan, which addresses how the Company stays ahead of the fundamental shifts affecting our customers. This includes the goal to accelerate the adoption of digital technology not only by Henry Schein's customers but also throughout the Company.

    Ms. Clark has been named Senior Vice President and Chief Global Customer Experience Officer, responsible for leading a new Global Customer Experience Organization that is focused on driving an exceptional customer experience across all of the Company's sales channels as well as global brand marketing strategy, including the Henry Schein brand. Ms. Benowitz has been named Senior Vice President and Chief Global Digital Transformation Officer, responsible for leading a new Global eCommerce Transformation Organization that will focus on accelerating the adoption of digital commerce technologies across our Company, driving the transformation of our business strategy and operations using digital technology, and enabling the rapid growth of digital sales revenue for the organization.

    "A primary goal of our new strategic plan is for customers to rely on Henry Schein for an exceptional experience, driven by a digital transformation across our Company and among our customers for the ultimate benefit of patients," said Stanley M. Bergman, Chairman and Chief Executive Officer, Henry Schein, Inc. "We are pleased to announce the appointment of Trinh and Leigh to our Executive Management Committee, both of whom have the energy, intelligence, passion, and experience necessary to drive success for this critical strategic goal.

    "Trinh and Leigh have distinguished themselves since joining our Company, both as individuals and as leaders who model the Team Schein values," Mr. Bergman said. "We are fortunate to have such a deep bench of executive talent to draw on to make our strategic plan come to life."

    A 15-year veteran of Henry Schein, Ms. Clark had been Vice President, Technology Enablement, North America Distribution Group. She reports to Brad Connett, the Chief Executive Officer of Henry Schein's North America Distribution Group.

    Ms. Clark has nearly 25 years of health care industry experience and has served in a variety of leadership roles at Henry Schein. Prior to joining Henry Schein, she was a founding member of eSurg, an online distributor of pharmaceutical, surgical, office, and medical supplies. Ms. Clark earned her Bachelor of Arts degree in Social Sciences from University of Washington.

    "I am honored to join the Executive Management Committee and excited by the opportunity to advance the critical work of delivering a consistently exceptional customer experience for our customers around the world," said Ms. Clark.

    A five-year veteran of the Company, Ms. Benowitz had been Vice President, Customer & Digital Experience and Global E-Commerce Platform (GEP) Transformation Officer. She will continue to lead the implementation of GEP, and will now report to Christopher Pendergast, Senior Vice President and Chief Technology Officer.

    Before joining Henry Schein, she had a successful career in the financial services industry, and held a variety of marketing and digital leadership positions at Citi. Ms. Benowitz earned her Bachelor of Arts in Economics from State University of New York at Albany and her Master of Business Administration from Fordham University.

    "It is a privilege to join the senior leadership team of Henry Schein and to help lead our digital transformation efforts at a time when technology is fundamentally changing every industry, including health care," said Ms. Benowitz.

    About Henry Schein, Inc.

    Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With nearly 22,000 TSMs Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

    Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

    A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories. The Company's sales reached $12.4 billion in 2021, and have grown at a compound annual rate of approximately 12.5 percent since Henry Schein became a public company in 1995.

    For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and Twitter.com/HenrySchein.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005699/en/

    Get the next $HSIC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    11/10/2023$70.00Hold → Buy
    Stifel
    8/8/2022$80.00Sell → Neutral
    UBS
    More analyst ratings

    $HSIC
    SEC Filings

    See more
    • SEC Form 11-K filed by Henry Schein Inc.

      11-K - HENRY SCHEIN INC (0001000228) (Filer)

      6/20/25 8:01:34 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - HENRY SCHEIN INC (0001000228) (Filer)

      6/9/25 8:30:38 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SD filed by Henry Schein Inc.

      SD - HENRY SCHEIN INC (0001000228) (Filer)

      5/30/25 4:18:14 PM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Henry Schein with a new price target

      Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

      2/14/25 7:05:26 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein upgraded by BofA Securities with a new price target

      BofA Securities upgraded Henry Schein from Underperform to Buy and set a new price target of $84.00 from $69.00 previously

      1/6/25 8:12:21 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Mizuho initiated coverage on Henry Schein with a new price target

      Mizuho initiated coverage of Henry Schein with a rating of Neutral and set a new price target of $75.00

      12/4/24 7:41:29 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Updated: Henry Schein to Participate in Upcoming Investor Conference in June

      Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in June: Jefferies Global Healthcare Conference at the Marriott Marquis hotel, New York City, on June 4, at 12:50 p.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With ap

      6/2/25 6:45:00 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein One Unveils The Catalyst Index, a Look into Dentistry's Top 10%

      Patient experience is the differentiator – The Catalyst Index reveals how top practices reduce friction to retain and engage patients Henry Schein One today announced the launch of The 2025 Catalyst Index, its exclusive report offering dental practices an unparalleled view into the strategies transforming performance across the industry. Built on years of trusted benchmarking and informed by Henry Schein One's most connected platform, the fourth annual report, The Catalyst Index, raises the bar by revealing the specific actions that distinguish the top 10% of DSOs and private practices. "We're at a turning point in dentistry," said Dr. Ryan Hungate, Chief Clinical and Strategy Officer, He

      5/20/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

      5/16/25 4:10:00 PM ET
      $HSIC
      $KKR
      Medical Specialities
      Health Care
      Investment Managers
      Finance

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Kkr Hawaii Aggregator L.P.

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      6/18/25 7:24:32 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Chairman, CEO Bergman Stanley M gifted 145 units of Common Stock par value $0.01 per shre, decreasing direct ownership by 0.04% to 323,747 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      6/17/25 4:36:56 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Director Daniel William K was granted 2,849 shares (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      6/16/25 5:36:46 PM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

      5/16/25 4:10:00 PM ET
      $HSIC
      $KKR
      Medical Specialities
      Health Care
      Investment Managers
      Finance
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities

    $HSIC
    Financials

    Live finance-specific insights

    See more
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

      4/8/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

      Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result

      2/25/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      11/13/24 3:30:01 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Henry Schein Inc.

      SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

      11/12/24 9:32:27 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      2/14/24 11:18:57 AM ET
      $HSIC
      Medical Specialities
      Health Care